Journal of Clinical Oncology
Articles in this Issue
The influence of advanced age on outcomes in patients with diffuse large B-cell lymphoma treated with CAR-T therapy.
7034 Background: Chimeric antigen receptor T-Cell (CAR-T) has emerged as a potentially curative treatment for diffuse larg...
ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from ER+/HER2− breast cancer.
TPS1155 Background: Endocrine therapy (ET) + cyclin dependent kinase 4/6 inhibitor (CDK4/6i) is the mainstay for the manag...
Clonal hematopoiesis-related outcomes associated with radioligand therapy in prostate cancer: A “real-world” analysis.
5045 Background: Radioligand therapy with radium-223 (Rad) and lutetium-177 (Plu) demonstrates notable hematologic toxicit...
New-onset inflammatory bowel disease associated with immune checkpoint inhibitor therapy: A real-world multicenter analysis.
11141 Background: Immune checkpoint inhibitors (ICIs) are increasingly used across a broad range of malignancies and are k...
Chronic condition cost burden among older Medicare cancer patients.
e23164 Background: With the rising comorbidity burden among cancer patients of older age, understanding the prevalence and...
Hematologic and cardiovascular outcomes of SGLT2 inhibitors in patients with chronic lymphocytic leukemia and type 2 diabetes: A real-world TriNetX analysis.
7050 Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) exhibit biologically plausible metabolic and immunomod...
PD-1 inhibition with camrelizumab in cervical cancer: A systematic review and meta-analysis.
e17515 Background: Cervical cancer is the fourth leading cause of cancer mortality in women worldwide. PD-L1 is expressed...
Is the investment in metastatic breast cancer research sufficient and aligned with patient priorities?
e13099 Background: To inform strategic investment in metastatic breast cancer (MBC) research, it is essential to understan...
Neoadjuvant treatment of QL1706 in patients with resectable microsatellite instability-high/mismatch repair-deficient colon cancer: Results from a phase 1b trial.
3620 Background: Immune checkpoint inhibitors in neoadjuvant setting have brought clinical benefits for patients with vari...
The efficacy and safety of postoperative adjuvant donafenib therapy for patients with high-risk recurrence hepatocellular carcinoma after radical resection: A multicenter retrospective study in China.
e16274 Background: Hepatectomy is a crucial treatment for long-term survival in patients with HCC; however, the high recur...
First-in-human phase I study of HSK41959, an MTA-cooperative PRMT5 inhibitor, in patients with <i>MTAP</i> -deleted advanced solid tumors.
e15097 Background: PRMT5 is an essential epigenetic regulator that drives cell proliferation. MTAP deletion, occurring in...
Early inpatient radiation for central nervous system (CNS) tumors: Timing, predictors, and in-hospital outcomes.
e14036 Background: Initiating radiation therapy (RT) early during acute CNS tumor admissions may mitigate complications. W...
Correlates of patient enrollment in a population-based randomized controlled trial of cascade genetic testing in families with hereditary cancer susceptibility.
10528 Background: Clinical trials that enroll patients through virtual approaches are growing but there is little informat...
A phase Ib/IIa study of BAT8010+BAT1006, an anti-HER2 monoclonal antibody-exatecan conjugate combined with an ADCC-enhanced HER2 mAb in patients with advanced solid tumors: Results from the 1L HER2-positive breast cancer cohort.
1046 Background: BAT8010 is an ADC targeting HER2, while BAT1006 is a humanized monoclonal antibody targeting another epit...
Real-world treatment patterns and outcomes among patients with high-risk and very high-risk non-metastatic prostate cancer.
e17120 Background: Patients with high-risk (HiR) and very high-risk (VHiR) non-metastatic prostate cancer (nmPC) are at in...
Temporal trends and disparities in liver cancer incidence in the United States, 1999–2022: A Joinpoint regression analysis.
e16307 Background: Liver cancer incidence has changed substantially in the United States over the past two decades, with n...
Neoadjuvant tyrosine kinase inhibitor therapy for unresectable locally advanced thyroid cancer: A systematic review and meta-analysis.
e18151 Background: Unresectable locally advanced thyroid cancers represent a rare clinical entity with a poor prognosis co...
Outcomes of neoadjuvant immunotherapy (NeoIO) in Merkel cell carcinoma.
9589 Background: Merkel cell carcinoma (MCC) is an aggressive malignancy with high rate of nodal and distant metastasis, l...
The future of oncology research: Replacing case report forms with mCODE-aligned electronic health record data for clinical trial data curation (Alliance).
e13661 Background: The process of data abstraction and curation represents a significant proportion of clinical trial cost...
Cardiovascular outcomes after bispecific T-cell-engager therapy in multiple myeloma: A propensity-matched real-world study.
e24007 Background: Bispecific T-cell engager (BiTE) therapies have emerged as highly effective immunotherapeutic agents fo...
Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase II study in patients with advanced <i>RET</i> fusion–positive non–small cell lung cancer (NSCLC).
8505 Background: RET-fusion positive NSCLC accounts for 1-2% of all lung cancers. Lunbotinib is a next gen brain-penetrant...
Multi-disciplinary discharge coordination team to overcome discharge barriers and address the risk of delayed discharges.
e23318 Background: Efficient discharge planning is essential in healthcare, especially for oncology patients with complex...
Identifying gastric cancer risk before cancer suspicion: <i>Helicobacter pylori</i> prevalence and virulence heterogeneity in a multicenter endoscopy cohort.
e22534 Background: Gastric cancer remains a leading cause of cancer mortality worldwide. Helicobacter...
Patent claim landscape of FDA Orange Book–listed oral oncology drugs: A systematic analysis of standard practice claims.
e23042 Background: Patents listed in the FDA Orange Book influence the timing of generic drug entry. While intended to pro...
Real-world treatment patterns and outcomes with olutasidenib after venetoclax in <i>IDH1</i> -mutated AML using EHR data.
e18514 Background: Venetoclax (VEN) plus a hypomethylating agent is standard front-line therapy for patients with AML inel...